Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

859.80INR
1 Apr 2015
Change (% chg)

-- (--)
Prev Close
Rs859.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
561,543
52-wk High
Rs869.70
52-wk Low
Rs430.05

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.45
Market Cap(Mil.): Rs365,985.50
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 37.22 39.17
EPS (TTM): -19.13 -- --
ROI: -- 16.24 15.58
ROE: -- 16.99 16.57
Search Stocks

U.S. class action asserts India's Ranbaxy manipulated FDA rules

MUMBAI - Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market.

14 May 2015

U.S. class action asserts Ranbaxy manipulated FDA rules

MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market.

14 May 2015

U.S. class action asserts India's Ranbaxy manipulated FDA rules

MUMBAI, May 14 - Indian generic drugmaker Ranbaxy Laboratories Ltd has been sued in a district court in the United States for allegedly manipulating U.S. Food and Drug Administration rules for years to keep rival generic drugs out of the market.

14 May 2015

Sun Pharma, not sated by Ranbaxy deal, may spend up to $7 billion on M&A - bankers

MUMBAI - Sun Pharmaceuticals Industries Ltd , emboldened by its takeover of domestic rival Ranbaxy Laboratories, is willing to spend as much as $7 billion on further acquisitions, bankers familiar with the generic drugmaker's strategy said.

28 Apr 2015

DEALTALK-Sun Pharma, not sated by Ranbaxy deal, may spend up to $7 bln on M&A -bankers

* Sun Pharma looking to buy overseas biosimilar assets - bankers

28 Apr 2015

BUZZ-Japan's Daiichi Sankyo gains on stake sale in Sun Pharma

** Daiichi Sankyo Co Ltd shares rise 2.6 pct after the company said it was selling a part or all of its stake in Indian drugmaker Sun Pharmaceutical Industries Ltd

21 Apr 2015

Sensex rises over 1 percent, posts first weekly gain in four

MUMBAI - The BSE Sensex and Nifty rose on Wednesday, posting their first weekly gain in four and the biggest since Jan. 23 week, as lenders rallied ahead of the Reserve Bank of India's policy review, while Sun Pharmaceutical Industries and Ranbaxy Laboratories surged ahead of a planned merger.

01 Apr 2015

Indian shares rise over 1 pct, post first weekly gain in 4

MUMBAI, April 1 - Indian shares rose on Wednesday, posting their first weekly gain in four and the biggest since Jan. 23 week, as banks rallied ahead of the central bank's policy review, while Sun Pharmaceutical Industries and Ranbaxy Laboratories surged ahead of a planned merger.

01 Apr 2015

Indian shares set to snap 3-week losing streak; drug makers rise

MUMBAI, April 1 - Indian shares rose on Wednesday, on track to snap a three-week losing streak, led by gains in pharmaceutical stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories ahead of the latter's amalgamation with the former.

01 Apr 2015

BUZZ-India's Ranbaxy hits record high before amalgamation with Sun Pharma

** Ranbaxy Laboratories Ltd rises as much as 5.1 pct to hit an all-time high

01 Apr 2015

Earnings vs. Estimates

Search Stocks